Table S4 from Elraglusib, a Glycogen Synthase Kinase 3β Inhibitor, plus Chemotherapy with or without Immunotherapy in Patients with Recurrent, Metastatic Salivary Gland Carcinoma

Glenn J. Hanna; Nicole Scarfo; Kee-Young Shin; Anne O’Neill; Veronica Bedard; Michael J. Dennis; Kartik Sehgal; Vickie Y. Jo; Kristine S. Wong; Andrey V. Ugolkov; Andrew Paul Mazar; Robert I. Haddad

doi:10.1158/1078-0432.31006830

Table S4 from Elraglusib, a Glycogen Synthase Kinase 3β Inhibitor, plus Chemotherapy with or without Immunotherapy in Patients with Recurrent, Metastatic Salivary Gland Carcinoma

2026 Open access

Read full text

Authors: Glenn J. Hanna, Nicole Scarfo, Kee-Young Shin, Anne O’Neill, Veronica Bedard, Michael J. Dennis, Kartik Sehgal, Vickie Y. Jo, Kristine S. Wong, Andrey V. Ugolkov, Andrew Paul Mazar, Robert I. Haddad

DOI: 10.1158/1078-0432.31006830

Cited by: 0

Abstract

Predictors of overall survival (univariate cox proportional hazards model)

Fields of Study & Subjects

Head and Neck Cancer Studies Salivary Gland Disorders and Functions Wnt/β-catenin signaling in development and cancer

Publication details

Publication date: 6 January 2026